We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Non-Invasive Test Detects Up To 42 Solid Tumors and Five Blood Cancers in Blood and Urine Samples

By LabMedica International staff writers
Posted on 27 Sep 2024
Print article
Image: The MCED test can screen for up to 42 solid tumors and five hematological tumors (Photo courtesy of 123RF)
Image: The MCED test can screen for up to 42 solid tumors and five hematological tumors (Photo courtesy of 123RF)

Cancer is now responsible for nearly 1 in 6 deaths worldwide. Each year, over 14 million people are diagnosed with cancer, and this number is expected to surpass 21 million by 2030. A major issue is that many cancer cases are detected too late. Approximately 70% of all cancer-related deaths stem from cancers for which there are no established screening tests, and these are often diagnosed at an advanced stage, making treatment more difficult. Even in countries with highly developed healthcare systems, a significant number of cancers are identified at a late stage, when successful treatment is more challenging. There is a pressing need for innovative, non-invasive screening tests to detect cancer in asymptomatic individuals, particularly during the early stages when treatment is most effective. A new Multi-Cancer Early Detection (MCED) test, using routine blood and urine samples and powered by a machine learning (ML) algorithm, now offers the potential to screen for up to 42 solid tumors and five hematological tumors.

Developed by Kience Inc. (Wilmington, DE, USA), the Venient Sx MCED test can accurately detect 42 types of solid tumors and 5 hematological tumors, which together represent 95.2% of all new cancer cases globally. It is capable of identifying cancer at early stages, even before symptoms appear, allowing for more successful treatment. Additionally, the test screens for up to 276 non-malignant diseases related to major bodily functions, systems, and overall metabolism, many of which are known risk factors for cancer.

The Venient Sx MCED test provides insights into the potential onset of diseases years in advance by analyzing clinical data, lab results, and lifestyle factors. The comprehensive, personalized report generated by the test suggests preventive measures to address both non-malignant diseases and potential cancer risks, helping to prevent their natural progression. Studies validating the Venient Sx MCED test have shown it achieves 95% sensitivity, 73% specificity, and 95% accuracy across 276 non-malignant conditions. Venient Sx MCED test has already obtained CE Mark and is currently under US certification.

Related Links:
Kience Inc.

New
Gold Member
Thyroid Stimulating Hormone Assay
TSH EIA 96 Test
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
C-Reactive Protein Test
mLabs CRP
New
Automated Nucleic Acid Extraction Instrument
EX9600

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The discovery of a new blood group has solved a 50- year-old mystery (Photo courtesy of 123RF)

Newly Discovered Blood Group System to Help Identify and Treat Rare Patients

The AnWj blood group antigen, a surface marker discovered in 1972, has remained a mystery regarding its genetic origin—until now. The most common cause of being AnWj-negative is linked to hematological... Read more

Microbiology

view channel
Image: The inbiome molecular culture ID technology has received FDA breakthrough device designation (Photo courtesy of inbiome)

Revolutionary Molecular Culture ID Technology to Transform Bacterial Diagnostics

Bacterial infections pose a major threat to public health, contributing to one in five deaths worldwide. Current diagnostic methods often take several days to provide results, which can delay appropriate... Read more

Pathology

view channel
Image: Confocal- & laminar flow-based detection scheme of intact virus particles, one at a time (Photo courtesy of Paz Drori)

Breakthrough Virus Detection Technology Combines Confocal Fluorescence Microscopy with Microfluidic Laminar Flow

Current virus detection often relies on polymerase chain reaction (PCR), which, while highly accurate, can be slow, labor-intensive, and requires specialized lab equipment. Antigen-based tests provide... Read more

Industry

view channel
Image: The GeneXpert system’s fast PCR Xpert tests can fight AMR and superbugs with fast and accurate PCR in one hour (Photo courtesy of Cepheid)

Cepheid Partners with Fleming Initiative to Fight Antimicrobial Resistance

Antimicrobial resistance (AMR) is responsible for over one million deaths globally each year and poses a growing challenge in treating major infectious diseases like tuberculosis, Escherichia coli (E.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.